Nathaniel Aviv Cohen1, Nitsan Maharshak2,3. 1. Department of Internal Medicine "B", Tel Aviv Medical Center, Tel Aviv, Israel. 2. Bacteriotherapy Clinic, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, 6 Weizman Street, Tel Aviv, 6423906, Israel. nitsanm@tlvmc.gov.il. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. nitsanm@tlvmc.gov.il.
Abstract
BACKGROUND AND AIMS: Fecal microbial transplantation (FMT) is an established successful treatment modality for recurrent Clostridium difficile infection (CDI). The safety profile and potential therapeutic advantages of FMT for diseases associated with dysbiosis and immune dysfunction have led to many publications, mainly case series, and while many studies and reviews have been published on the use of FMT for inflammatory bowel disease (IBD), its potential use for other disease conditions has not been thoroughly reviewed. The aim of this review was to investigate the evidence surrounding the use of FMT in conditions other than IBD and CDI. METHODS: A PubMed search was performed using the terms "Fecal microbiota transplantation" OR "FMT" OR "Bacteriotherapy." RESULTS: A total of 26 articles describing the use of FMT in a variety of both intra-and extraintestinal disease conditions including gastrointestinal, hematologic, neurologic, metabolic, infectious, and autoimmune disorders have been included in this review and have demonstrated some positive results. The studies included were case reports, case series, controlled trials, and cohort studies. CONCLUSIONS: The findings of these studies demonstrate that FMT, particularly in conditions associated with gastrointestinal dysbiosis, shows promise to provide another effective tool in the therapeutic armament of the practicing physician. FMT was found to be possibly effective in various diseases, mostly associated with enteric dysbiosis or with immune dysfunction. Randomized clinical studies on large populations should be performed to explore the effectiveness of this therapy, and basic research studies should be designed to gain understanding of the mechanisms through which impact these disorders.
BACKGROUND AND AIMS: Fecal microbial transplantation (FMT) is an established successful treatment modality for recurrent Clostridium difficileinfection (CDI). The safety profile and potential therapeutic advantages of FMT for diseases associated with dysbiosis and immune dysfunction have led to many publications, mainly case series, and while many studies and reviews have been published on the use of FMT for inflammatory bowel disease (IBD), its potential use for other disease conditions has not been thoroughly reviewed. The aim of this review was to investigate the evidence surrounding the use of FMT in conditions other than IBD and CDI. METHODS: A PubMed search was performed using the terms "Fecal microbiota transplantation" OR "FMT" OR "Bacteriotherapy." RESULTS: A total of 26 articles describing the use of FMT in a variety of both intra-and extraintestinal disease conditions including gastrointestinal, hematologic, neurologic, metabolic, infectious, and autoimmune disorders have been included in this review and have demonstrated some positive results. The studies included were case reports, case series, controlled trials, and cohort studies. CONCLUSIONS: The findings of these studies demonstrate that FMT, particularly in conditions associated with gastrointestinal dysbiosis, shows promise to provide another effective tool in the therapeutic armament of the practicing physician. FMT was found to be possibly effective in various diseases, mostly associated with enteric dysbiosis or with immune dysfunction. Randomized clinical studies on large populations should be performed to explore the effectiveness of this therapy, and basic research studies should be designed to gain understanding of the mechanisms through which impact these disorders.
Authors: Alanna M Spees; Christopher A Lopez; Dawn D Kingsbury; Sebastian E Winter; Andreas J Bäumler Journal: PLoS Pathog Date: 2013-11-21 Impact factor: 6.823
Authors: Felix Broecker; Jochen Klumpp; Markus Schuppler; Giancarlo Russo; Luc Biedermann; Michael Hombach; Gerhard Rogler; Karin Moelling Journal: Cold Spring Harb Mol Case Stud Date: 2016-01
Authors: Nicholas Arpaia; Clarissa Campbell; Xiying Fan; Stanislav Dikiy; Joris van der Veeken; Paul deRoos; Hui Liu; Justin R Cross; Klaus Pfeffer; Paul J Coffer; Alexander Y Rudensky Journal: Nature Date: 2013-11-13 Impact factor: 49.962
Authors: Uri Obolski; José Lourenço; Craig Thompson; Robin Thompson; Andrea Gori; Sunetra Gupta Journal: Proc Natl Acad Sci U S A Date: 2018-03-06 Impact factor: 11.205
Authors: Perttu Lahtinen; Eero Mattila; Veli-Jukka Anttila; Jyrki Tillonen; Matti Teittinen; Pasi Nevalainen; Seppo Salminen; Reetta Satokari; Perttu Arkkila Journal: World J Gastroenterol Date: 2017-10-21 Impact factor: 5.742